Study of Panobinostat in Patients With Neuroendocrine Tumors

• ClinicalTrials.gov Identifier: NCT00985946
• Recruitment Status: Terminated
• First Posted: September 29, 2009
• Results First Posted: July 17, 2017
• Last Update Posted: July 17, 2017
• Sponsor: University of Wisconsin, Madison
• Collaborator: Novartis Pharmaceuticals
• Information provided by (Responsible Party): University of Wisconsin, Madison

Study Description

Brief Summary:

This summary will use Panobinostat (LBH589) in patients with neuroendocrine tumors to see how the patient's tumor responds to panobinostat. Additionally, this study will examine how long it takes neuroendocrine tumor patient's cancer to progress while taking the drug and examine the overall survival of patients using panobinostat. Also, the study will examine the toxicity and tolerability of panobinostat in the patient population. Finally, this study will look at the effect of panobinostat on Notch 1 signaling before and after treatment with panobinostat.

Condition or disease	Intervention/treatment	Phase
Neuroendocrine Tumors	Drug: panobinostat (LBH589)	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial of Panobinostat in Patients With Neuroendocrine Tumors
• Study Start Date: May 2010
• Actual Primary Completion Date: April 2015
• Actual Study Completion Date: April 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: panobinostat; This is a single arm trial. All patients will take panobinostat	Drug: panobinostat (LBH589); Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.

Outcome Measures

Primary Outcome Measures :

1. Tumor Response Rate of Patients With Gastrointestinal Neuroendocrine Tumors Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. [ Time Frame: every 8 weeks, up to 5 years ]
   Confirmed anti-tumor response rate will be validated by the Response Evaluation Criteria in Solid Tumors (RECIST). All participants included in the study will be assessed for response to the proposed panobinostat treatment, even if there are protocol treatment deviations. Each participant will be assigned one of the following categories: complete response, partial response, stable disease, progressive disease, early death from malignant disease, early death from toxicity, early death because of other cause, or unknown.

Secondary Outcome Measures :

1. Number of Participants With Toxicities [ Time Frame: up to 5 years ]
   Evaluate the toxicity and tolerability of panobinostat in the patient population
2. Evaluate the Time to Progression for Patients With Gastrointestinal Neuroendocrine Tumors Treated With Panobinostat [ Time Frame: Up to 5 years ]
3. Delineate the Expression of Notch 1 in Neuroendocrine Tumor Samples Before and During Treatment With Panobinostat [ Time Frame: Pre-treatment and up to week 12 ]
   The expression of Notch 1 in neuroendocrine tumor samples will be evaluated prior to Cycle 1 Day 1 dose and at the end of Cycle 2 of treatment of treatment.
4. Evaluate the Overall Survival of Patients With Gastrointestinal Neuroendocrine Tumors Treated With Panobinostat [ Time Frame: Up to 5 years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically confirmed, metastatic, low grade neuroendocrine neoplasms. Small cell lung cancers, paragangliomas, and pheochromocytomas are excluded
• Must have measurable disease as defined by RECIST
• 4 weeks from completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration. Concurrent octreotide is allowed.
• Not allowed to be on concurrent chemotherapy or radiation
• 18 years of age or older
• ECOG Performance status of equal to or less than 2
• Able to sign and date a written informed consent prior to participation in the study
• Baseline MUGA or ECHO must demonstrate LVEF greater than or equal to the lower limit of the institutional normal
• Must have the following laboratory criteria: Neutrophil count greater than 1500/mm3, platelet count greater than 100,000/mm3L, hemoglobin greater than or equal to 9 g/dL, AST/SGOT and ALT/SGPT less than or equal to 2.5 x ULN, serum bilirubin less than or equal to 1.5 x ULN, serum creatinine less than or equal to 1.5 x ULN, total serum calcium greater than or equal to LLN, serum potassium greater than or equal to LLN, serum sodium greater than or equal to LLN, serum albumin greater than or equal to LLN or 3g/dl,
• Women of child bearing potential must have a negative urine pregnancy test within 72 hours of first administration of study treatment and must be willing to use two methods of contraception
• Patients with a history of hypertension must be well controlled (to less than 150/90 mmHg) on a stable regimen of anti-hypertensive therapy

Exclusion Criteria:

• Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
• Patients who will need valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat treatment
• Impaired cardiac function including any of the following: Screening ECG with a QTc greater than 450 msec, patients with congenital long QT syndrome, history of unsustained ventricular tachycardia, any history of ventricular fibrillation or torsades de pointes, bradycardia defined as heart rate less than 50 beats per minutes, patients with a myocardial infarction or unstable angina within 6 months of study entry, congestive heart failure, right bundle branch block or left anterior hemiblock
• Uncontrolled hypertension
• Unresolved diarrhea greater than CTCAE grade 1
• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat
• Other concurrent sever and/or uncontrolled medical conditions
• Patients with a history of another primary malignancy that, in the opinion of the investigator, would interfere with the assessment of the primary endpoint of the study
• Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C, baseline testing is not required
• Any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
• Any medication which may cause QTc prolongation or inducing torsades de pointes
• Use of concomitant medications that may interact with panobinostat

Contacts and Locations

Locations

United States, Wisconsin

University of Wisconsin, Madison

Madison, Wisconsin, United States, 53792

Sponsors and Collaborators

University of Wisconsin, Madison

Novartis Pharmaceuticals

Investigators

• Principal Investigator: Noelle LoConte, MD; University of Wisconsin, Madison

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jin N, Lubner SJ, Mulkerin DL, Rajguru S, Carmichael L, Chen H, Holen KD, LoConte NK. A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist. 2016 Jul;21(7):785-6. doi: 10.1634/theoncologist.2016-0060. Epub 2016 Jun 3.

• Responsible Party: University of Wisconsin, Madison
• ClinicalTrials.gov Identifier: NCT00985946 History of Changes
• Other Study ID Numbers: 2010-0050 (CO08209); CLBH589BUS38T
• First Posted: September 29, 2009
• Results First Posted: July 17, 2017
• Last Update Posted: July 17, 2017
• Last Verified: June 2017

Additional relevant MeSH terms:

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Panobinostat; Antineoplastic Agents; Histone Deacetylase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action